Premium
The effect of fenoldopam, a dopaminergic agonist, on renal hemodynamics
Author(s) -
Allison Nancy L,
Dubb Jeffrey W,
Ziemniak John A,
Alexander Fred,
Stote Robert M
Publication year - 1987
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1987.29
Subject(s) - fenoldopam , renal blood flow , chemistry , dopamine agonist , endocrinology , medicine , agonist , renal function , vasodilation , effective renal plasma flow , blood pressure , receptor
Fenoldopam, a dopaminergic agonist, was administered intravenously to 18 healthy male subjects in doses ranging from 0.025 to 1.0 μg/kg/min for 2 hours. Three subjects were studied in a three‐way crossover of fenoldopam at doses of 0.025, 0.10, and 0.50 μg/kg/min. Fenoldopam decreased diastolic blood pressure and increased pulse rate without changing systolic blood pressure. Fenoldopam produced dose‐related increases in para‐aminohippuric acid clearance up to 75% at the 0.50 μg/kg/min dose. This increase in renal blood flow was accompanied by increases in urine volume, water, and solute excretion; glomerular filtration rate was unchanged. Doses greater than 0.25 μg/kg/min caused flushing and nasal congestion. The dopamine receptor antagonist metoclopramide (0.1 mg/kg/hr) did not block the systemic hemodynamic effects of fenoldopam but attenuated the increase in para‐aminohippuric acid clearance. Fenoldopam plasma levels achieved steady state between 30 and 120 minutes after the start of the infusion and were linear with respect to infusion rate. Our findings show that intravenous fenoldopam causes systemic arteriolar vasodilation, accompanied by renal vasodilation and increased sodium excretion. Clinical Pharmacology and Therapeutics (1987) 41, 282–288; doi: 10.1038/clpt.1987.29